Cerebrospinal fluid glial fibrillary acidic protein provides differential diagnostic value in some forms of dementias
Pontus Eriksson, Tobias Skillback, Silke Kern, Linus Jönsson, Kaj Blennow, Maria Eriksdotter, Henrik Zetterberg · 2025
Read Cerebrospinal fluid glial fibrillary acidic protein provides differential diagnostic value in some forms of dementias by Pontus Eriksson, Tobias Skillback, Silke Kern, Linus Jönsson, Kaj Blennow, Maria Eriksdotter, Henrik Zetterberg (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715276.txt.
Description
Pontus Eriksson and co-authors published this study in two thousand twenty-five on a spinal fluid protein called GFAP and its power to tell dementias apart. GFAP marks a kind of brain support-cell reaction, and labs are often asked to measure it, but its worth for diagnosis was unclear.
The team merged lab records with the Swedish dementia registry, covering more than nineteen hundred people across ten diagnoses. GFAP levels did differ by disease. Parkinson's dementia ran lowest, while vascular dementia and late-onset Alzheimer's ran high. The protein split some pairs of diseases cleanly, like vascular dementia from frontotemporal dementia. It failed to split others. The authors say GFAP can help on a group level in hard cases. It is one more clue for the clinic, not a stand-alone test.
Catalog record
| CREATOR | Pontus Eriksson, Tobias Skillback, Silke Kern, Linus Jönsson, Kaj Blennow, Maria Eriksdotter, Henrik Zetterberg |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |